版本:
中国

BRIEF-Gilead receives approval in Canada for Vemlidy for treatment of chronic hepatitis b virus infection

June 19 Gilead Sciences Inc

* Gilead receives approval in Canada for Vemlidy™ (tenofovir alafenamide) for the treatment of chronic hepatitis b virus infection

* Gilead Sciences Inc - Health Canada has granted a notice of compliance for vemlidy 25mg tablets

* Gilead Sciences - patients in vemlidy arm also experienced numerically higher rates of normalization of blood serum alanine aminotransferase (alt) levels

* Gilead Sciences Inc - study 108, study 110 met their primary endpoint of non-inferiority to viread Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐